Scarica l'app Stockscreener
2.155
12.75%
-0.315
Pre-mercato:
2.22
0.065
+3.02%
Precedente Chiudi:
$2.47
Aprire:
$2.5
Volume 24 ore:
4.16M
Relative Volume:
2.01
Capitalizzazione di mercato:
$573.53M
Reddito:
-
Utile/perdita netta:
$-208.38M
Rapporto P/E:
-1.7958
EPS:
-1.2
Flusso di cassa netto:
$-156.57M
1 W Prestazione:
-9.07%
1M Prestazione:
-12.75%
6M Prestazione:
+9.95%
1 anno Prestazione:
-41.44%
Intervallo 1D:
$2.11
$2.50
Intervallo di 1 settimana:
$2.11
$2.52
Portata 52W:
$1.105
$5.00
Autolus Therapeutics Plc Adr Stock (AUTL) Company Profile
Nome
Autolus Therapeutics Plc Adr
Settore
Industria
Telefono
44 20 3829 6230
Indirizzo
THE MEDIAWORKS, LONDON
Confronta AUTL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AUTL
Autolus Therapeutics Plc Adr
|
2.155 | 657.36M | 0 | -208.38M | -156.57M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Autolus Therapeutics Plc Adr Stock (AUTL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-18 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-11-15 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2023-11-09 | Iniziato | Deutsche Bank | Buy |
| 2023-03-27 | Ripresa | Wells Fargo | Overweight |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2021-06-14 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | JP Morgan | Overweight |
| 2020-07-22 | Iniziato | SunTrust | Buy |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2019-09-23 | Iniziato | Needham | Buy |
| 2019-05-17 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-24 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Autolus Therapeutics Plc Adr Borsa (AUTL) Ultime notizie
Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates - GlobeNewswire Inc.
How GLDD stock performs during market volatilityAlgorithmic Forecast for Swing Trading Picks - Newser
Why IGNEP stock attracts strong analyst attentionFree Day Trading Signals With High Precision - Newser
When is the best time to buy GRAIL LLC stockFree Smart Allocation Stock Pick Insights - Newser
Is a relief rally coming for Zhibao Technology Inc. holdersSmart Stock Forecast Using AI Algorithms - Newser
Statistical indicators supporting GDV.PRH’s strengthFree Stable Entry High Return Opportunities - Newser
Can machine learning forecast Peoples Bancorp of North Carolina Inc. recoveryHigh Win Rate Strategy with Stop Protection - Newser
What makes Boqii Holding Limited Depositary Receipt stock price move sharplyFree Market Entry and Exit Point Tips - Newser
Autolus Therapeutics plc ADR: Weathering Stock Market Storms with 637.41M Market Cap - investchronicle.com
LyondellBasell Industries NV (LYB) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Top chart patterns to watch in Stevanato Group S.p.A.Free High Return Stock Focus With Safety - Newser
P 500Real-Time Equity Price Action Analysis - Newser
Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks With ‘Strong Buy’ Ratings - Barchart.com
TER’s Stock Market Adventure: -40.87% YTD Growth Amidst Volatility - investchronicle.com
Globe Life Inc (GL) Stock: Navigating a Year of Volatility - investchronicle.com
Autolus Therapeutics’ (AUTL) Buy Rating Reaffirmed at Needham & Company LLC - Defense World
European Commission approves Autolus’ cell therapy for adult leukemia By Investing.com - Investing.com South Africa
European Commission approves Autolus’ cell therapy for adult leukemia - Investing.com India
Will A Mark Precious Metals Inc. stock benefit from interest rate changesDaily Upside Movement Prediction With Data - Newser
Cambridge Investment Research Advisors Inc. Sells 2,160 Shares of Invesco KBW Property & Casualty Insurance ETF (NASDAQ:KBWP) - Defense World
Allspring Global Investments Holdings LLC Sells 439,622 Shares of Dr. Reddy’s Laboratories Ltd (NYSE:RDY) - Defense World
1,867 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by DAVENPORT & Co LLC - Defense World
DAVENPORT & Co LLC Trims Holdings in Janus Henderson Short Duration Income ETF (NYSEARCA:VNLA) - Defense World
Vontobel Holding Ltd. Lowers Holdings in Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) - Defense World
Allspring Global Investments Holdings LLC Raises Holdings in Broadstone Net Lease, Inc. (NYSE:BNL) - Defense World
Wealth Enhancement Advisory Services LLC Takes $258,000 Position in Taylor Morrison Home Corporation (NYSE:TMHC) - Defense World
Vontobel Holding Ltd. Buys 49,643 Shares of Tilray Brands, Inc. (NASDAQ:TLRY) - Defense World
TELUS International (Cda) (TSE:TIXT) Trading 2.1% Higher – What’s Next? - Defense World
Closing Figures: Autolus Therapeutics plc ADR (AUTL)’s Negative Finish at 2.05, Down -3.30 - DWinneX
NOV Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com
Autolus shares surge 77% following InvestingPro’s April Fair Value signal By Investing.com - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel By Investing.com - Investing.com South Africa
Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens By Stocktwits - Investing.com India
EMA committee endorses Autolus’ leukemia therapy obe-cel - Investing.com
Autolus Therapeutics plc ADR (AUTL) Has A Gold Mine On Its Hands - Stocksregister
Autolus reports $9M in Q1 product revenue, gains UK approval By Investing.com - Investing.com South Africa
Autolus reports $9M in Q1 product revenue, gains UK approval - Investing.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
There is no doubt that Autolus Therapeutics plc ADR (AUTL) ticks all the boxes. - Sete News
Autolus Therapeutics plc ADR (AUTL) receives a Buy rating from Goldman - knoxdaily.com
AUTL’s valuation metrics: A comprehensive analysis - uspostnews.com
Market Resilience: Autolus Therapeutics plc ADR (AUTL) Finishes Weak at 1.33, Down -5.00 - DWinneX
Market Update: Goosehead Insurance Inc (GSHD) Sees Positive Movement, Closing at 99.54 - DWinneX
How Do Things Look For Autolus Therapeutics plc ADR (NASDAQ: AUTL) In The Short-Term? - Stocksregister
UK approves Autolus leukemia therapy with conditions By Investing.com - Investing.com India
For Autolus Therapeutics plc ADR [AUTL], Analyst sees a rise to $7.60. What next? - dbtnews.com
UK approves Autolus leukemia therapy with conditions - Investing.com
Autolus Therapeutics plc ADR [NASDAQ: AUTL] Sees Decrease in Stock Value - knoxdaily.com
Market cap of i-80 Gold Corp [IAUX] reaches 279.54M – now what? - dbtnews.com
Daiwa Securities lifts Bilibili Inc ADR [BILI] price estimate. Who else is bullish? - dbtnews.com
Market Watch: Autolus Therapeutics plc ADR (AUTL)’s Noteworthy Gain, Closing at 1.60 - DWinneX
Autolus Therapeutics Plc Adr Azioni (AUTL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.91%
3.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):